Washington Blade - December 2, 2005
Lisa Sterman

These powerful medications have saved the lives of thousands of people living with HIV/AIDS, including many gay men across the country. This important anniversary reminds us of the tremendous progress that has been made in AIDS treatment over the past decade as well as how much remains to be done to improve HIV/AIDS care for those living with the disease.

The approval of the first HAART regimen was truly historic. Many of us remember how remarkable it was to believe for the first time that those we loved might survive HIV/AIDS.

A disease that was once considered a death sentence gradually transformed into a serious, yet potentially manageable condition for many. For the first time in years, obituary sections in gay publications began to shrink.

In the decade since combination therapy was introduced, deaths from AIDS have dropped by more than 60 percent in the United States, falling from a peak of more than 48,000 in 1995 to approximately 18,000 in 2003. Almost overnight, HAART created a generation of HIV survivors.

BUT SURVIVAL CAME with a price. Patients on early HAART therapies often had a terrible time with medication schedules. Many treatment regimens were taken five times a day and carried complex meal requirements.

A typical patient would roll out of bed, swallow a handful of pills on an empty stomach, take more pills later with food and grapefruit juice (to aid with absorption), eat two hours later, then begin the process anew with dinner.

Many also experienced serious side effects like severe fatigue, diarrhea, nerve-related pain and the stigmatizing body-altering syndrome known as lipodystrophy.

Patients demanded improvements and medical science produced something unprecedented in infectious disease medicine: a stunning array of new and better drugs.

Today, HIV treatment is much less complex than a decade ago, requiring fewer pills and fewer doses, often with fewer side effects. Treatment advances are helping people with HIV to live and plan for more normal lives.

Progress in HIV research is likely to continue; the world's first complete HIV regimen in a single once-daily pill is expected in 2006.

Of course, treatment hurdles still remain, including side effects and drug resistance. In a recent study of modern HAART, up to 89 percent of patients experienced at least one drug-related side effect. That needs to improve.

Ongoing research is currently underway to develop additional therapies in new drug classes in order to better treat those with advanced or highly resistant strains of HIV.

ANOTHER HUGE CHALLENGE is reducing the rate of new infections. Forty thousand more people are infected with HIV in the United States every year.

Optimism about improving treatment should not lull anyone into believing that HIV is not still a serious disease, one that is still much better avoided than treated.

Access and timely treatment is also still a challenge for many. While therapy options have greatly improved, not everyone is benefiting from quality HIV/AIDS care.

Too many people are being diagnosed with AIDS-related conditions in the Emergency Room, at a late stage in their disease, and are missing the benefits of earlier treatment. This is particularly true for the poor and people of color, including African-American and Latino gay men, who traditionally have experienced barriers in accessing health services.

Globally, greater efforts are needed to treat the millions of people living with HIV disease in developing countries.

The challenges ahead are daunting. But physicians, scientists, healthcare workers and activists can be proud of the significant improvements that we have made over the past decade enhancing the lives of people living with HIV/AIDS.

Our work continues.

***

Dr. Lisa Sterman is a San Francisco HIV specialist and associate professor at the University of California San Francisco. She can be reached at lisa.sterman_md@hotmail.com.

051202
WB051201

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .